Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects
Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects With Primary Immunodeficiency Diseases
Sponsor: Baxalta Innovations GmbH, now part of Shire
A PHASE4 clinical study on Primary Immunodeficiency Diseases (PID), this trial is completed. The trial is conducted by Baxalta Innovations GmbH, now part of Shire and has accumulated 15 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Mar 2021 — Feb 2023 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
▶ Show 10 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE4
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Aug 2019 — May 2020 [monthly]
Recruiting PHASE4
-
Jun 2019 — Aug 2019 [monthly]
Recruiting PHASE4
-
Jul 2018 — Jun 2019 [monthly]
Recruiting PHASE4
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE4
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE4
-
Nov 2017 — Apr 2018 [monthly]
Recruiting PHASE4
-
Oct 2017 — Nov 2017 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baxalta Innovations GmbH, now part of Shire
- Baxalta now part of Shire
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Athens, Greece , Belfast, United Kingdom , Bordeaux, France , Bratislava, Slovakia , Bristol, United Kingdom , Brno, Czechia , Budapest, Hungary , Cardiff, United Kingdom , Copenhagen, Denmark and 9 more locations